Head and Neck Cancer New Indication: Enfortumab Vedotin for Head and Neck Cancer Ulas D. Bayraktar, MD 2025-03-02
Mantle cell lymphoma New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-03-02
Non-Small Cell Lung Cancer New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC Ulas D. Bayraktar, MD 2025-03-02
Hepatocellular Carcinoma New Reference: Lenvatinib and Pembrolizumab for HCC Ulas D. Bayraktar, MD 2025-03-02
Nasopharyngeal Cancer New Protocol: Pembrolizumab and Bevacizumab for Nasopharyngeal Cancer Ulas D. Bayraktar, MD 2025-03-02
Non-Small Cell Lung Cancer New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer Ulas D. Bayraktar, MD 2025-02-07
Chronic Lymphocytic Leukemia New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab Ulas D. Bayraktar, MD 2025-02-07
Colorectal Cancer New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer Ulas D. Bayraktar, MD 2025-01-31
GastroEsophageal Cancer New Reference: Periop FLOT in Esophageal Cancer Ulas D. Bayraktar, MD 2025-01-24
Breast Cancer New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease Ulas D. Bayraktar, MD 2025-01-24
